pd 153035 has been researched along with sirolimus in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Balmain, A; Beug, H; Oft, M; Petritsch, C | 1 |
2 other study(ies) available for pd 153035 and sirolimus
Article | Year |
---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
TGF-beta inhibits p70 S6 kinase via protein phosphatase 2A to induce G(1) arrest.
Topics: Activin Receptors, Type I; Androstadienes; Animals; Cells, Cultured; Chromones; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epithelial Cells; ErbB Receptors; Fibroblasts; G1 Phase; Morpholines; Mutation; Phosphoprotein Phosphatases; Phosphorylation; Protein Biosynthesis; Protein Phosphatase 2; Protein Serine-Threonine Kinases; Quinazolines; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Ribosomal Protein S6 Kinases; S Phase; Signal Transduction; Sirolimus; Smad2 Protein; Trans-Activators; Transforming Growth Factor beta; Wortmannin | 2000 |